Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV study of tailored therapy with peg interferon alfa 2b and ribavirin for patients with genotype 3 and high viral load. Genotype 3 extended treatment for HCV (GET-C study).

Trial Profile

Phase IV study of tailored therapy with peg interferon alfa 2b and ribavirin for patients with genotype 3 and high viral load. Genotype 3 extended treatment for HCV (GET-C study).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms GET-C
  • Sponsors Schering-Plough
  • Most Recent Events

    • 28 Jul 2009 Actual patient number (146) added as reported by ClinicalTrials.gov.
    • 21 Mar 2008 Status change from suspended to discontinued, as reported by clinicaltrials.gov.
    • 17 Jan 2008 The expected completion date for this trial is now 1 Aug 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top